Agios scores its second new drug approval, ivosidenib heads to the AML market

Agios scores its second new drug approval, ivosidenib heads to the AML market

Submitted by admin on July 20, 2018 - 11:52am
Source: 
Endpoints
News Tags: 
Agios Pharmaceuticals
ivosidenib (AG-120)
AML
acute myeloid leukemia
Headline: 
Agios scores its second new drug approval, ivosidenib heads to the AML market
snippet: 
Agios has hit another big goal in its decade-long track record. The FDA today signaled the accelerated approval of ivosidenib (AG-120) for advanced acute myeloid leukemia.

Do Not Allow Advertisers to Use My Personal information